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ABSTRACT: Re(I) tricarbonyl polypyridine-based complexes are particularly attractive metal complexes in the field of inorganic chemical 
biology due to their luminescent properties, ease of conjugation to targeting biomolecules and the possibility to prepare their “hot” 99mTc 
analogs for radioimaging. In this study, we prepared and characterized a novel, “clickable” complex, [Re(2,2’-bipyridine)(3-
ethynylpyridine)(CO)3](BF4) ([Re(CO)3(bipy)(py-alkyne)](BF4)), exhibiting the characteristic luminescent properties and moderate 
cytotoxicity of this general class of compound. Using Cu(I)-catalyzed “click” chemistry, the complex was efficiently attached to a lipidated 
peptide known to increase cell permeability, namely the myristoylated HIV-1 Tat peptide (myr-Tat), to give Re-myr-tat. Fluorescence 
microscopy localization in human cervical cancer cells (HeLa) confirmed enhanced cellular uptake of Re-myr-Tat compared with 
[Re(CO)3(bipy)(py-alkyne)](BF4), and cytotoxicity studies showed that this resulted in an increase in potency to a level comparable with 
cisplatin (13.0 ± 2.0 M).  
Re(I) tricarbonyl [2 + 1] complexes based on polypyridine-
derived ligands, such as (Re(bipy)(L)(CO)3) (L = monodentate 
ligand), have attracted considerable attention in the last decade as 
catalysts,1 photosensitizers in photocatalytic water reduction2, 3 and 
CO-releasing molecules.4 They remain, however, best known for 
their outstanding photochemical properties (large Stokes shifts, 
long emission lifetimes, resistance to photobleaching),5 which 
make them excellent candidates for cellular imaging and ion 
sensing applications.6-14 Their use in these areas has been spurred 
on by their good biocompatibility15 and the possibility to 
incorporate targeting vectors via the pyridine or bipyridine-based 
ligands.9, 16, 17 Significantly, the “hot” 99mTc analogs of these Re 
compounds could also be prepared, making them promising 
multimodal agents.16, 18-20 
While Re(I) tricarbonyl polypyridine-based complexes are 
normally only moderately toxic, or essentially non-toxic, several 
other Re(I) compounds have been reported to be as active or even 
more potent than cisplatin.8, 21-28 Given how active many 
organometallic compounds are known to be against cancer cells 
lines,29-34 it is surprising that the cytotoxic potential of these Re(I) 
complexes has not yet been fully explored, especially in light of 
their aforementioned advantages. 
In this work, we aimed to improve the cytotoxicity of a Re(I) 
compound, namely [Re(CO)3(bipy)(py-alkyne)]+, whose 
moderate cytotoxicity was discovered by serendipity in the course 
of a separate study. To do this, we envisaged enhancing cellular 
uptake of the complex via conjugation to a myristoylated HIV-1 
Tat peptide (Scheme 1). HIV-1 Tat is a membrane translocation 
sequence from HIV, while myristic acid is a saturated linear fatty 
acid that naturally occurs as a post-translational protein 
modification. Both myristic acid and myristoylated Tat peptide 
were shown to increase the cellular uptake of compounds when 
conjugated to them. 35, 36 In this study, the Re complex was 
appended to an azide-modified myristoylated Tat peptide via 
“click” chemistry. Over the past few years, click chemistry has been 
successfully employed to couple other organometallic compounds 
to peptides, either by solid-phase or solution-phase methods.37-40 
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Scheme 1. Bioconjugation of [Re(CO)3(bipy)(py-alkyne)]+ to 
a myristoylated Tat peptide.
  [Re(CO)3(bipy)(py-alkyne)](BF4) was synthesized following 
an established literature procedure employed for Re(I) fac-
tricarbonyl bipyridyl complexes with a substituted pyridine 
ligand.41 In brief, the initially formed Re tricarbonyl bipyridyl 
chloride complex was activated via halide abstraction as the 
corresponding acetonitrile complex. The acetonitrile ligand was 
then displaced by 3-ethynylpyridine. The formation and purity of 
the desired product was confirmed by 1H- and 13C-NMR, HR-MS 
(Figures S1–3) and elemental analysis. Of note, loss of the 
monodentate pyridine ligand (m/z 427.0 [M-py]+) during 
ionization was observed in the MS spectrum (Figure S3). 
[Re(CO)3(bipy)(py-alkyne)](BF4) exhibits the typical 
photophysical properties for this type of Re(I) complex.10, 17, 25, 42-50 
The UV-vis absorbtion spectra showed intense bands at 250–330 
nm (absorption coefficients around 15,000 M-1cm-1) and a weaker  
shoulder at 350–360 nm (about 4,500 M-1cm-1) (Figure S5). The 
former are normally attributed to spin allowed intraligand 
transitions (1IL =(π→π*) (bipyridine and pyridine), while the 
latter is assigned to spin-allowed metal-to-ligand charge transfer 
(1MLCT) [dπ(Re) → π*(bipy)]. Upon irradiation in the MLCT 
band (355 nm), [Re(CO)3(bipy)(py-alkyne)](BF4) displayed a 
strong emission centered at 550 nm (Figure S6). Long, sub-
microsecond luminescence lifetimes (Table 1) and large Stokes 
shift indicate the phosphorescent nature of the emission,51 which 
can be ascribed to a triplet 3MLCT [dπ(Re) → π*(bipy)] 
transition, as observed for similar complexes.4, 12 Typical emission 
lifetimes and quantum yields of Re(CO)3(bipy)(L) complexes 
encompass a relatively broad range (0.05–9.6 μs and 0.002–0.59, 
respectively).52 The values measured for [Re(CO)3(bipy)(py-
alkyne)](BF4)  are, in fact, very close to those of structurally 
similar Re(CO)3(bipy)(L) complexes, such as isothiocyanate-
substituted pyridine complexes.17 Of note, shorter lifetimes in water 
compared to acetonitrile can be explained by the greater polarity of 
water, which stabilizes the 3MLCT excited state, thus lowering its 
energy and facilitating non-radiative processes.53, 54 The complex 
itself can be solubilized in pure water up to 0.79 ± 0.13 mM 
(25 °C). 
Table 1. Emission lifetimes and  quantum yields of 
[Re(CO)3(bipy)(py-alkyne)](BF4) 
Solvent Aerated  Degased Quantum yields 
(aerated) 
H2O  117 ± 2 ns 128 ± 3 ns 0.0048 ± 0.0005 
Acetonitrile 168 ± 6 ns 329 ± 1 ns 0.011 ± 0.001 
 
Since some studies have previously noted the loss of the 
monodentate pyridine ligand in solution for this type of complex,16, 
18-20 the stability of [Re(CO)3(bipy)(py-alkyne)](BF4) in water 
and human blood plasma was assessed. Following an experimental 
procedure similar to that previously reported by our group,28, 55-57 
the complex and diazepam (used as an internal standard due to its 
known stability in blood plasma and water) were incubated in 
human plasma or double distilled water for up to 72 h. The aqueous 
phase was then extracted with dichloromethane and the organic 
phase analyzed by UPLC-MS. Two peaks corresponding to 
[Re(CO)3(bipy)(py-alkyne)]+ (1.7 min, m/z 530.1 [M]+, 427.1 
[M-ligand]+) and diazepam (2.1 min, m/z 285.2 [M+H]+) could be 
clearly identified (Figure S9-12). The percentage of decomposed 
[Re(CO)3(bipy)(py-alkyne)]+ was then calculated using 
diazepam as the internal standard. As shown on Figure 1, 
decomposition proceeded significantly faster in human blood 
plasma (half-life of approx. 22 h) than pure water (half-life of 
approx. 5 days), probably due to the substitution of the pyridine 
ligand by stonger donor groups present in blood plasma proteins 
(e.g. histidine or cysteine). These results are consistent with the 
recent study by the Valliant group, which showed a marked 
dependence of the pyridine ligand lability on its basicity/leaving 
group ability.16 The plasma stability of [Re(CO)3(bipy)(py-
alkyne)](BF4) is on par with the most stable compounds reported 
by Valliant and co-workers.16  
The azide-modified myristoylated Tat peptide (myr-Tat) was 
prepared via standard solid-phase peptide synthesis techniques and 
then purified by preparative HPLC to give a sticky yellow solid, 
which was unambiguously characterized by HR-MS and HPLC 
(Figures S13–14). It was then successfully conjugated to 
[Re(CO)3(bipy)(py-alkyne)](BF4) via Cu(I)-catalyzed click 
chemistry using similar experimental conditions to those reported 
by Fokin and co-workers.58 The crude compound was purified by 
preparative HPLC to yield Re-myr-Tat as a pale yellow solid, 
which was characterized by UPLC-MS and MALDI-TOF (Figures 
S15–16). A single peak was observed in the UPLC-MS 
chromatogram and – consistent with the MS spectrum of complex 
– both the desired product and fragments resulting from pyridine 
ligand dissociation appeared in the MS  spectrum (m/z 338.9 [M-
Re(CO)3(bipy)+6H]6+, 406.4 [M- Re(CO)3(bipy)+5H]5+, 491.6 
[M+4H]5+, 507.8 [M-Re(CO)3(bipy)+4H]4+, 614.2 [M+3H]4+, 
818.7 [M+2H]3+). In the MALDI-TOF spectrum, only the 
fragmented product (m/z 2026.4 [M-Re(CO)3(bipy)+H]+) was 
detected due to the harsher ionization conditions compared to ESI-
MS. The presence of the fac-Re(CO)3 core in the Re-myr-Tat 
bioconjugate was unambiguously confirmed by the presence of the 
CO stretching bands in the IR spectrum, which appeared in the 
same range to that of [Re(CO)3(bipy)(py-alkyne)](BF4)  (Figure 
S17). The influence of the myr-Tat moiety on the lipophilicity of 
the resulting bioconjugate Re-myr-Tat was evaluated by 
measuring the distribution coefficient between octanol and 
 
Figure 1. [Re(CO)3(bipy)(py-alkyne)]+ stability in human blood 
plasma and water (double distilled) at 37 °C.  
 phosphate buffer, pH 7.01 (logD7.01), using a similar procedure to 
one used by our group for Ru complexes.59 Interestingly, although 
myr-Tat contains both a long lipophilic fatty acid chain and a 
highly positively-charged peptide sequence, the net effect is an 
increase in lipophilicity, namely from a logD7.01 of -0.36 ± 0.05 for 
[Re(CO)3(bipy)(py-alkyne)]+ to 0.86 ± 0.15 for Re-myr-Tat. 
This change could potentially improve the cellular uptake of Re-
myr-Tat, as higher lipophilicity can favor the entry of compounds 
into cells, and hence enhance the cytotoxicity.59-63  
With the desired organometallic complex and bioconjugate in 
hand, we investigated the intracellular fate of both compounds in 
human cervical cancer cells (HeLa) by fluorescence microscopy. 
The cells were first incubated for 2 h with an appropriate 
concentration of each compound, then fixed with formaldehyde 
and finally imaged. Figure 2 shows a pronounced difference in 
emission intensity between the cells treated with 
[Re(CO)3(bipy)(py-alkyne)](BF4) (B) or Re-myr-Tat (C). 
Indeed, while the concentration of Re-myr-Tat in the cell medium 
was five times lower than that of the complex, the cells incubated 
with Re-myr-Tat appeared much brighter, indicating significantly 
higher uptake (it is important to keep in mind that the intensity of 
the emission signal of a compound in the cells sometimes fails to 
correlate with uptake, as luminescence can be quenched in the 
cellular environment).28, 64 In terms of subcellular localization, the 
complex and the bioconjugate were visualized in the cytoplasm 
(although weak signals were sometimes detected in the nucleoli of 
cells incubated with the complex) – a localization typically 
observed for this type of Re complex.10, 12, 15, 16 Of note, whilst the 
HIV-1 Tat peptide sequence has been reported to promote nuclear 
localization,65 with a myristoylated Tat derivative dual-labeled with 
Gd-DOTA and fluorescein previously shown to stain both nucleoli 
and nuclear membranes,36 this was not the case for Re-myr-Tat. 
Our microscopy images were recordered at a relatively low Re-
myr-Tat concentration that left most of the cells alive after 2 h. The 
Gd-DOTA myr-Tat derivative, on the other hand, was imaged at a 
much higher concentration (260 M), at which about 60% of the 
cells were already dying.36 When HeLa cells were incubated with a 
higher concentration (2.5-fold increase) of Re-myr-Tat, 
localization in nuclear membrane and nucleoli was also observed 
(Figure S18). However, the cells appeared to be already slightly 
affected by the conjugate at this concentration, so this change in 
localization could be due to toxin stress. 
Next, the cytotoxicity of [Re(CO)3(bipy)(py-alkyne)](BF4) 
and Re-myr-Tat towards HeLa cells was evaluated by incubating 
the cells with increasing concentrations of the compounds for 48 h 
and quantifying cell viability using the resazurin assay.66 The 
toxicity of our compounds was compared with that of an 
established metal-containing anti-cancer drug, namely cisplatin. 
Although several studies report on the cytotoxicity of Re(I) 
tricarbonyl bipyridine-pyridine complexes, their anti-proliferative 
effect has generally been found to range from non-existent to 
moderate; [Re(CO)3(bipy)(py-alkyne)](BF4) does not deviate 
from this trend (Table 2). A series of similar complexes, namely 
Re(phen)(diaminopy)(CO)3, display IC50 values 2–3-fold higher 
than cisplatin.25 Significantly, however, the coupling of 
[Re(CO)3(bipy)(py-alkyne)]+ to the myristoylated Tat peptide 
was found to significantly increase the cytotoxicity of the resulting 
bioconjugate, bringing it on par with cisplatin.  
Table 2. Cytotoxicity data (IC50 values) for 
[Re(CO)3(bipy)(py-alkyne)](BF4), Re-myr-Tat and cisplatin 
towards HeLa cells. 
Compounds HeLa IC50 (μM) 
[Re(CO)3(bipy)(py-alkyne)]+ 29.9 ± 6.1 
Re-myr-Tat 13.0 ± 2.0 
Cisplatin 9.1 ± 2.8 
* Experiments were performed in triplicates. 
In conclusion, in this work,we prepared and characterized a new 
“clickable” Re(I) complex, which could be successfully conjugated 
to an azide-containing myristoylated Tat peptide to give Re-myr-
Tat. Cytotoxicity and biological studies with HeLa cells revealed 
that the anti-proliferative effect of the complex could be enhanced 
considerably by the addition of a cell uptake-enhancing 
biomolecule.  
 
 
Figure 2. Fluorescence microscopy of HeLa cells fixed after 2 h: A) untreated cells; B) treated with [Re(CO)3(bipy)(py-alkyne)](BF4) at 100 
μM; C) treated with Re-myr-Tat at 20 μM. 
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ABBREVIATIONS 
Bipy – bipyridine 
DOTA – 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
ESI – electrospray ionization 
HeLa – cervical cancer cell line 
HIV – human immunodeficiency virus 
HPLC – high-performance liquid chromatography 
L – ligand 
NMR – nuclear magnetic resonance 
HR-MS – high resolution mass spectroscopy 
MALDI-TOF – matrix-assisted laser desorption ionization time-of-
flight 
MLCT – metal-to-ligand charge transfer 
Py – pyridine 
Tat – “trans-activator of transcription”, here a cell-permeating peptide 
sequence derived from HIV-1 Tat protein 
UPLC – ultra-performance liquid chromatography 
UV-vis – ultra-violet-visible light 
 
REFERENCES 
(1) Kutal, C.; Weber, M. A.; Ferraudi, G.; Geiger, D. A mechanistic 
investigation of the photoinduced reduction of  carbon dioxide mediated 
by  tricarbonylbromo(2,2’-bipyridine)rhenium(I). Organometallics 
1985, 4, 2161-2166. 
(2) Probst, B.; Rodenberg, A.; Guttentag, M.; Hamm, P.; Alberto, R. A 
highly stable rhenium-cobalt system for photocatalytic H2 production: 
unraveling the performance-limiting steps. Inorg. Chem. 2010, 49, 6453-
6460. 
(3) Probst, B.; Guttentag, M.; Rodenberg, A.; Hamm, P.; Alberto, R. 
Photocatalytic H2 production from water with rhenium and cobalt 
complexes. Inorg. Chem. 2011, 50, 3404-3412. 
(4) Pierri, A. E.; Pallaoro, A.; Wu, G.; Ford, P. C. A luminescent and 
biocompatible photocorm. J. Am. Chem. Soc. 2012, 134, 18197-18200. 
(5) Worl, L. A.; Duesing, R.; Chen, P.; Ciana, L. D.; Meyer, T. J. 
Photophysical properties of polypyridyl carbonyl complexes of 
rhenium(I). J. Chem. Soc., Dalton Trans. 1991, 849-858. 
(6) Lo, K. K.-W.; Choi, A. W.-T.; Law, W. H.-T. Applications of luminescent 
inorganic and organometallic transition metal complexes as 
biomolecular and cellular probes. Dalton Trans. 2012, 41, 6021-6047. 
(7) Lo, K. K.-W.; Zhang, K. Y.; Li, S. P.-Y. Recent exploitation of 
luminescent rhenium(I) tricarbonyl polypyridine complexes as 
biomolecular and cellular probes. Eur. J. Inorg. Chem 2011, 3551-3568. 
(8) Louie, M.-W.; Choi, A. W.-T.; Liu, H.-W.; Chan, B. T.-N.; Lo, K. K.-W. 
Synthesis, emission characteristics, cellular studies, and bioconjugation 
properties of luminescent rhenium(I) polypyridine complexes with a 
fluorous pendant. Organometallics 2012, 31, 5844-5855. 
(9) Louie, M.-W.; Liu, H.-W.; Lam, M. H.-C.; Lam, Y.-W.; Lo, K. K.-W. 
Luminescent rhenium(I) polypyridine complexes appended with an α-d-
glucose moiety as novel biomolecular and cellular probes. Chem. Eur. J. 
2011, 17, 8304-8308. 
(10) Fernàndez-Moreira, V.; Ortego, M. L.; Williams, C. F.; Coogan, M. P.; 
Villacampa, M. D.; Gimeno, M. C. Bioconjugated rhenium(I) complexes 
with amino acid derivatives: synthesis, photophysical properties, and cell 
imaging studies. Organometallics 2012, 31, 5950-5957. 
(11) Thorp-Greenwood, F. L.; Balasingham, R. G.; Coogan, M. P. 
Organometallic complexes of transition metals in luminescent cell 
imaging applications J. Organomet. Chem. 2012, 714, 12-21. 
(12) Choi, A. W.-T.; Poon, C.-S.; Liu, H.-W.; Cheng, H.-K.; Lo, K. K.-W. 
Rhenium(I) polypyridine complexes functionalized with a 
diaminoaromatic moiety as phosphorescent sensors for nitric oxide. New 
J. Chem. 2013, 37, 1711-1719. 
(13) Clede, S.; Lambert, F.; Sandt, C.; Kascakova, S.; Unger, M.; Harte, E.; 
Plamont, M.-A.; Saint-Fort, R.; Deniset-Besseau, A.; Gueroui, Z.; 
Hirschmugl, C.; Lecomte, S.; Dazzi, A.; Vessieres, A.; Policar, C. 
Detection of an estrogen derivative in two breast cancer cell lines using a 
single core multimodal probe for imaging (SCoMPI) imaged by a panel 
of luminescent and vibrational techniques. Analyst 2013, 138, 5627-
5638. 
(14) Clede, S.; Lambert, F.; Sandt, C.; Gueroui, Z.; Refregiers, M.; Plamont, 
M.-A.; Dumas, P.; Vessieres, A.; Policar, C. A rhenium tris-carbonyl 
derivative as a single core multimodal probe for imaging (SCoMPI) 
combining infrared and luminescent properties. Chem. Comm. 2012, 48, 
7729-7731. 
(15) Fernandez-Moreira, V.; Thorp-Greenwood, F. L.; Amoroso, A. J.; Cable, 
J.; Court, J. B.; Gray, V.; Hayes, A. J.; Jenkins, R. L.; Kariuki, B. M.; 
Lloyd, D.; Millet, C. O.; Williams, C. F.; Coogan, M. P. Uptake and 
localisation of rhenium fac-tricarbonyl polypyridyls in fluorescent cell 
imaging experiments. Org. Biomol. Chem. 2010, 8, 3888-3901. 
(16) Pitchumony, T. S.; Banevicius, L.; Janzen, N.; Zubieta, J.; Valliant, J. F. 
Isostructural Nuclear and Luminescent Probes Derived From Stabilized 
[2 + 1] Rhenium(I)/Technetium(I) Organometallic Complexes. Inorg. 
Chem. 2013, 52, 13521-13528. 
(17) Lo, K. K.-W.; Ng, D. C.-M.; Hui, W.-K.; Cheung, K.-K. Luminescent 
rhenium(I) polypyridine complexes with an isothiocyanate moiety-
versatile labelling reagents for biomolecules. Dalton Trans. 2001, 2634-
2640. 
(18) Gottschaldt, M.; Koth, D.; Müller, D.; Klette, I.; Rau, S.; Görls, H.; 
Schäfer, B.; Baum, R. P.; Yano, S. Synthesis and structure of novel sugar-
substituted bipyridine complexes of rhenium and 99m-technetium. 
Chem. Eur. J. 2007, 13, 10273-10280. 
(19) Zhang, X.; Chen, X. Preparation and characterization of 99mTc(CO)3-
BPy-RGD complex as alphav beta-3 integrin receptor-targeted imaging 
agent. Appl. Radiat.  Isotopes 2007, 65, 70-78. 
(20) Alberto, R. The chemistry of technetium–water complexes within the 
manganese triad: challenges and perspectives. Eur. J. Inorg. Chem 2009, 
21-31. 
 (21) Zhang, J.; Vittal, J. J.; Henderson, W.; Wheaton, J. R.; Hall, I. H.; Hor, T. 
S. A.; Yan, Y. K. Tricarbonylrhenium(I) complexes of phosphine-
derivatized amines, amino acids and a model peptide: structures, 
solution behavior and cytotoxicity. J. Organomet. Chem. 2002, 650, 123-
132. 
(22) Wang, W.; Yan, Y. K.; Hor, T. S. A.; Vittal, J. J.; Wheaton, J. R.; Hall, I. H. 
Synthesis, X-ray structures, and cytotoxicity of rhenium(I) carbonyl 2-
(dimethylamino)ethoxide complexes. Polyhedron 2002, 21, 1991-1999. 
(23) Bartholoma, M. D.; Vortherms, A. R.; Hillier, S.; Ploier, B.; Joyal, J.; 
Babich, J.; Doyle, R. P.; Zubieta, J. Synthesis, cytotoxicity, and insight 
into the mode of action of Re(CO)3 thymidine complexes. 
ChemMedChem 2010, 5, 1513-1529. 
(24) Can, D.; Peindy N'Dongo, H. W.; Spingler, B.; Schmutz, P.; Raposinho, 
P.; Santos, I.; Alberto, R. The [(Cp)M(CO)3] (M=Re, 99mTc) building 
block for imaging agents and bioinorganic probes: perspectives and 
limitations. Chem. Biodivers. 2012, 9, 1849-1866. 
(25) Choi, A. W.-T.; Louie, M.-W.; Li, S. P.-Y.; Liu, H.-W.; Chan, B. T.-N.; 
Lam, T. C.-Y.; Lin, A. C.-C.; Cheng, S.-H.; Lo, K. K.-W. Emissive 
behavior, cytotoxic activity, cellular uptake, and pegylation properties of 
new luminescent rhenium(I) polypyridine poly(ethylene glycol) 
complexes. Inorg. Chem. 2012, 51, 13289-13302. 
(26) Ho, J.; Lee, W. Y.; Koh, K. J. T.; Lee, P. P. F.; Yan, Y.-K. Rhenium(I) 
tricarbonyl complexes of salicylaldehyde semicarbazones: synthesis, 
crystal structures and cytotoxicity. J. Inorg. Biochem. 2013, 119, 10-20. 
(27) Viola-Villegas, N.; Rabideau, A. E.; Cesnavicious, J.; Zubieta, J.; Doyle, 
R. P. Targeting the folate receptor (FR): imaging and cytotoxicity of 
Re(I) conjugates in FR-overexpressing cancer cells. ChemMedChem 
2008, 3, 1387-1394. 
(28) Kitanovic, I.; Can, S.; Alborzinia, H.; Kitanovic, A.; Pierroz, V.; 
Leonidova, A.; Pinto, A.; Spingler, B.; Ferrari, S.; Molteni, R.; Steffen, A.; 
Metzler-Nolte, N.; Wolfl, S.; Gasser, G. Photophysical, theoretical and 
biological evaluation and cell death mechanisms of a Re(I) 
organometallic complex. Chem. Eur. J. 2013, 20, 2496-2507. 
(29) Gasser, G.; Ott, I.; Metzler-Nolte, N. Organometallic anticancer 
compounds. J. Med. Chem. 2010, 54, 3-25 and references therein. 
(30) Gasser, G.; Metzler-Nolte, N. The potential of organometallic complexes 
in medicinal chemistry. Curr. Opin. Chem. Biol. 2012, 16, 84-91 and 
references therein. 
(31) Hartinger, C. G.; Metzler-Nolte, N.; Dyson, P. J. Challenges and 
opportunities in the development of organometallic anticancer drugs. . 
Organometallics 2012, 31, 5677-5685 and references therein. 
(32) Bruijincx, P. C. A.; Sadler, P. J. New trends for metal complexes with 
anticancer activity. Curr. Opin. Chem. Biol. 2008, 12, 197-206 and 
references therein. 
(33) Hartinger, C. G.; Dyson, P. J. Bioorganometallic chemistry - from 
teaching paradigms to medicinal applications. Chem. Soc. Rev. 2009, 38, 
391-401 and references therein. 
(34) Jaouen, G.; Metzler-Nolte, N. Medicinal organometallic chemistry; 
Springer-Verlag, 2010  
(35) Nelson, A. R.; Borland, L.; Allbritton, N. L.; Sims, C. E. Myristoyl-based 
transport of peptides into living cells. Biochemistry 2007, 46, 14771-
14781. 
(36) Sturzu, A.; Klose, U.; Echner, H.; Beck, A.; Gharabaghi, A.; Kalbacher, 
H.; Heckl, S. Cellular uptake of cationic gadolinium-DOTA peptide 
conjugates with and without N-terminal myristoylation. Amino Acids 
2009, 37, 249-255. 
(37) Gasser, G.; Hüsken, N.; Köster, S. D.; Metzler-Nolte, N. Synthesis of 
organometallic PNA oligomers by click chemistry. Chem. Comm. 2008, 
3675-4677. 
(38) Gasser, G.; Jäger, K. Z., M.; Bergmann, R.; Steinbach, J.; Stephan, H.; 
Metzler-Nolte, N. Preparation, 99mTc-labeling and biodistribution 
studies of a PNA oligomer containing a new ligand derivative of 2,2´-
dipicolylamine. J. Inorg. Biochem. 2010, 104, 1133-1140. 
(39) Patra, M.; Gasser, G.; Bobukhov, D.; Merz, K.; Shtemenko, A. V.; 
Metzler-Nolte, N. Sequencial insertion of three different organometallics 
into a versatile building block containing a PNA backbone. Dalton Trans. 
2010, 39, 5617-5619. 
(40) Pfeiffer, H.; Rojas, A.; Niesel, J.; Schatzschneider, U. Sonogashira and 
"Click" reactions in the N-terminal and side chain functionalization of 
peptides with [Mn(CO)3(tpm)]+-based CO releasing molecules (tpm = 
tris(pyrazolyl)methane). Dalton Trans. 2009, 4292-4298. 
(41) Amoroso, A. J.; Coogan, M. P.; Dunne, J. E.; Fernandez-Moreira, V.; 
Hess, J. B.; Hayes, A. J.; Lloyd, D.; Millet, C.; Pope, S. J. A.; Williams, C. 
Rhenium fac tricarbonyl bisimine complexes: biologically useful 
fluorochromes for cell imaging applications. Chem. Commun. 2007, 
3066-3068. 
(42) Wrighton, M.; Morse, D. L. Nature of the lowest excited state in 
tricarbonylchloro-1,10-phenanthrolinerhenium(I) and related 
complexes. J. Am. Chem. Soc. 1974, 96, 998-1003. 
(43) Caspar, J. V.; Meyer, T. J. Application of the energy gap law to 
nonradiative, excited-state decay. J. Phys. Chem. A 1983, 87, 952-957. 
(44) Sullivan, B. P. Large solvatochromism of metal-to-ligand charge-transfer 
transitions in organometallic complexes of rhenium(I). J. Phys. Chem. A 
1989, 93, 24-26. 
(45) Kalyanasundaram, K. Luminescence and redox reactions of the metal-to-
ligand charge-transfer excited state of tricarbonylchloro-
(polypyridyl)rhenium(I) complexes. J. Chem. Soc., Faraday Trans. 1986, 
82, 2401-2415. 
(46) Tapolsky, G.; Duesing, R.; Meyer, T. J. Synthetic control of excited-state 
properties in ligand-bridged complexes of rhenium(I). Intramolecular 
energy transfer by an electron-transfer/energy-transfer cascade. Inorg. 
Chem. 1990, 29, 2285-2297. 
(47) Zipp, A. P.; Sacksteder, L.; Streich, J.; Cook, A.; Demas, J. N.; DeGraff, B. 
A. Luminescence of rhenium(I) complexes with highly sterically 
hindered alpha-diimine ligands. Inorg. Chem. 1993, 32, 5629-5632. 
(48) Stufkens, D. J.; Vlçek Jr, A. Ligand-dependent excited state behaviour of 
Re(I) and Ru(II) carbonyl-diimine complexes. Coord. Chem. Rev. 1998, 
177, 127-179. 
(49) Thornton, N. B.; Schanze, K. S. A chromophore-quencher-based 
luminescence probe for DNA. Inorg. Chem. 1993, 32, 4994-4995. 
(50) Lo, K. K.-W.; Hui, W.-K.; Ng, D. C.-M. Novel rhenium(I) polypyridine 
biotin complexes that show luminescence enhancement and lifetime 
elongation upon binding to avidin. J. Am. Chem. Soc. 2002, 124, 9344-
9345. 
(51) Uppal, B. S.; Booth, R. K.; Ali, N.; Lockwood, C.; Rice, C. R.; Elliott, P. I. 
P. Synthesis and characterisation of luminescent rhenium tricarbonyl 
complexes with axially coordinated 1,2,3-triazole ligands. Dalton Trans. 
2011, 40, 7610-7616. 
(52) Lo, K. K.-W.; Choi, A. W.-T.; Law, W. H.-T. Applications of luminescent 
inorganic and organometallic transition metal complexes as 
biomolecular and cellular probes. Dalton Trans. 2012, 41, 6021-6047. 
(53) Kuimova, M. K.; Alsindi, W. Z.; Blake, A. J.; Davies, E. S.; Lampus, D. J.; 
Matousek, P.; McMaster, J.; Parker, A. W.; Towrie, M.; Sun, X.-Z.; 
Wilson, C.; George, M. W. Probing the solvent dependent photophysics 
of fac-[Re(CO)3(dppz-X2)Cl] (dppz-X2 = 11,12-X2-dipyrido[3,2-a:2',3'-
c]phenazine); X = CH3, H, F, Cl, CF3). In Inorg. Chem.; American 
Chemical Society, 2008; pp. 9857-9869. 
(54) Sacksteder, L.; Lee, M.; Demas, J. N.; DeGraff, B. A. Long-lived, highly 
luminescent rhenium(I) complexes as molecular probes: intra- and 
intermolecular excited-state interactions. J. Am. Chem. Soc. 1993, 115, 
8230-8238. 
(55) Patra, M.; Ingram, K.; Pierroz, V.; Ferrari, S.; Spingler, B.; Keiser, J.; 
Gasser, G. Ferrocenyl derivatives of the anthelminc praziquantel: design, 
synthesis and biological evaluation. J. Med. Chem. 2012, 55, 8790-8798. 
(56) Patra, M.; Ingram, K.; Pierroz, V.; Ferrari, S.; Spingler, B.; Gasser, R. B.; 
Keiser, J.; Gasser, G. (η-Praziquantel)Cr(CO)3 derivatives with 
remarkable in vitro anti-schistosomal activity. Chem. Eur. J. 2013, 19, 
2232-2235. 
(57) Patra, M.; Ingram, K.; Leonidova, A.; Pierroz, V.; Ferrari, S.; Robertson, 
M. N.; Todd, M. H.; Keiser, J.; Gasser, G. In vitro metabolic profile and 
in vivo antischistosomal activity studies of (η-Praziquantel)Cr(CO)3 
derivatives. J. Med. Chem. 2013, 56, 9192-9198. 
(58) Chan, T. R.; Hilgraf, R.; Sharpless, K. B.; Fokin, V. V. Polytriazoles as 
copper(I)-stabilizing ligands in catalysis. Org. Lett. 2004, 6, 2853-2855. 
(59) Pierroz, V.; Joshi, T.; Leonidova, A.; Mari, C.; Schur, J.; Ott, I.; Spiccia, 
L.; Ferrari, S.; Gasser, G. Molecular and Cellular Characterization of the 
Biological Effects of Ruthenium(II) Complexes Incorporating 2-Pyridyl-
 2-pyrimidine-4-carboxylic Acid. J. Am. Chem. Soc. 2012, 134, 20376-
20387. 
(60) Ghezzi, A.; Aceto, M.; Cassino, C.; Gabano, E.; Osella, D. Uptake of 
antitumor platinum(II)-complexes by cancer cells, assayed by 
inductively coupled plasma mass spectrometry (ICP-MS). J. Inorg. 
Biochem. 2004, 98, 73-78. 
(61) Puckett, C. A.; Ernst, R. J.; Barton, J. K. Exploring the cellular 
accumulation of metal complexes. Dalton Trans. 2010, 39, 1159-1170. 
(62) Puckett, C. A.; Barton, J. K. Methods to explore cellular uptake of 
ruthenium complexes. J.  Am. Chem. Soc. 2006, 129, 46-47. 
(63) Mari, C.; Pierroz, V.; Rubbiani, R.; Patra, M.; Hess, J.; Spingler, B.; 
Oehninger, L.; Schur, J.; Ott, I.; Salassa, L.; Ferrari, S.; Gasser, G. DNA 
intercalating RuII polypyridyl complexes as effective photosensitizers in 
photodynamic therapy. 2014, submited. 
(64) Gasser, G.; Pinto, A.; Neumann, S.; Sosniak, A. M.; Seitz, M.; Merz, K.; 
Heumann, R.; Metzler-Nolte, N. Synthesis, characterisation and 
bioimaging of a fluorescent rhenium-containing PNA bioconjugate. 
Dalton Trans. 2012, 41, 2304-2313. 
(65) Vivès, E.; Brodin, P.; Lebleu, B. A truncated HIV-1Tat protein basic 
domain rapidly translocates through the plasma membrane and 
accumulates in the cell nucleus. J. Biol. Chem. 1997, 272, 16010-16017. 
(66) Ahmed, S. A.; Gogal, R. M. J.; Walsh, J. E. A new rapid and simple non-
radioactive assay to monitor and determine the proliferation of 
lymphocytes: an alternative to [3H]thymidine incorporation assay. J. 
Immunol. Methods 1994, 170, 211-224. 
 
  
 
 
 
